---
title: "BioMarin Secures $2 Billion Term Loan to Fund Amicus Therapeutics Acquisition"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/274202263.md"
datetime: "2026-01-29T21:07:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274202263.md)
  - [en](https://longbridge.com/en/news/274202263.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274202263.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/274202263.md) | [繁體中文](https://longbridge.com/zh-HK/news/274202263.md)


# BioMarin Secures $2 Billion Term Loan to Fund Amicus Therapeutics Acquisition

BioMarin Pharmaceutical Inc. has completed the syndication of a new $2 billion senior secured term loan B facility, in addition to an $800 million term loan A facility, as part of its pending acquisition of Amicus Therapeutics, Inc. The financing package also includes a $600 million senior secured revolving credit facility expected to be entered into in connection with the acquisition. Additionally, BioMarin has priced a $850 million offering of 5.500% senior unsecured notes due 2034 at par. The proceeds from these transactions, along with cash on hand, are intended to fund the consideration for the acquisition of Amicus Therapeutics and related expenses. The closing of the notes offering is expected on February 12, 2026, subject to customary closing conditions. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioMarin Pharmaceutical Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF74559) on January 29, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [iShares Global Healthcare ETF (IXJ.US)](https://longbridge.com/en/quote/IXJ.US.md)
- [ARK Genomic Revolution ETF (ARKG.US)](https://longbridge.com/en/quote/ARKG.US.md)
- [Amicus Therapeutics, Inc. (FOLD.US)](https://longbridge.com/en/quote/FOLD.US.md)
- [iShares US Pharmaceuticals ETF (IHE.US)](https://longbridge.com/en/quote/IHE.US.md)
- [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md)
- [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md)
- [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md)
- [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/en/quote/IBBQ.US.md)
- [Vanguard Health Care ETF (VHT.US)](https://longbridge.com/en/quote/VHT.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md)
- [BioMarin Pharmaceutical Inc. (BMRN.US)](https://longbridge.com/en/quote/BMRN.US.md)

## Related News & Research

- [BioMarin Pharmaceutical Highlights Growth Plan, VOXZOGO Milestones, and Amicus Deal at Conference](https://longbridge.com/en/news/279015256.md)
- [CSP International Publishes Disclosure on V2D Création Acquisition](https://longbridge.com/en/news/278778570.md)
- [Cipher Pharmaceuticals Delivers Record 2025 Results and Primes for Next Acquisition Phase](https://longbridge.com/en/news/278950215.md)
- [Oragenics receives HREC approval, begins Phase IIa ONP-002 site initiation in Australia](https://longbridge.com/en/news/278776483.md)
- [13:06 ETHall Render Represents Centurion Foundation in Rhode Island Hospital Acquisition, Preserving Essential Health Care Services](https://longbridge.com/en/news/278427087.md)